Introduction
Aristolochic acid (AA), an extract of Aristolochia species, is a mixture of structurally related nitrophenanthrene carboxylic acids, mainly aristolochic acid I (AAI) and aristolochic acid II (AAII) (1) . In alternative medicine, Aristolochia plant extracts have been used as anti-inflammatory agents (2) . However, AA is a strong genotoxic nephrotoxin and carcinogen in humans. AA has been associated with the development of a progressive renal fibrosis [aristolochic acid nephropathy (AAN)] and urothelial cancer in AAN patients (3) (4) (5) (6) . Also, AA exposure is linked to Balkan endemic nephropathy (BEN), a similar type of kidney fibrosis with malignant transformation of the urothelium (7, 8) .
The carcinogenic effects of AA also have been observed in rodents. AA induces tumours in the forestomach, kidney and urothelial tract of rats (9) (10) (11) (12) (13) . In mice, AA treatment results in forestomach carcinoma, adenocarcinoma in the glandular stomach, kidney adenomas, lung carcinomas and haemangiomas of the uterus (10) (11) (12) . Based on evidence from humans and rodents, the International Agency for Research on Cancer has classified herbal remedies containing AA and AA itself as Group I human carcinogens (14, 15) . In 2001, the U.S. Food and Drug Administration issued an advisory warning health care professionals that consumption of products with AA resulted in several life-threatening adverse events and published a list of botanical products that contain AA (16) .
AA-induced cytotoxicity has been observed in several species. Acute tubular damage occurred after a single intravenous injection of 1 mg/kg body weight (bw) in rabbits and after a dose of ,1 mg/kg bw/day given for 3 days in humans (17, 18) . In rats and mice, acute renal failure followed administration of single doses of 20 or 30 mg/kg bw or higher, respectively, indicating that kidney is the target organ for toxicity in both species. In Wistar rats, renal lesions developed in a dose-dependent manner within 3 days of receiving a single dose of 10, 50 or 100 mg/kg bw by gastric tube (19) . In contrast, renal dysfunction and hypocellular interstitial sclerosis developed at 4 and 6 months in Wistar rats given an intraperitoneal (i.p.) AA dose of 5 mg/kg bw/day for 4 months (20) . Renal failure with interstitial fibrosis was observed in salt-depleted Wistar rats receiving daily subcutaneous injections of 10 mg/kg bw AA for 35 days, whereas rats receiving 1 mg/kg bw AA exihibited urothelial dysplasia and slight tubular atrophy (12) . This indicates that 1 and 10 mg/kg bw AA are cytotoxic doses for Wistar rats. New Zealand White rabbits given 0.10 mg/kg bw/day AA i.p. developed impaired renal function at 16 months and extensive interstitial fibrosis at 17 months (21) .
Both in vitro and in vivo metabolism studies have identified the principle metabolites of AAI and AAII as aristolactam I and II, respectively (22, 23) . During bioactivation, AAI and AAII undergo reduction of a nitro group to form reactive cyclic nitrenium ions with delocalised charge, which can interact with the exocyclic amino groups of deoxyadenosine and deoxyguanosine, resulting in the preferential formation of purine adducts (1) . Studies from rodents and AAN patients demonstrated that AA forms covalent DNA adducts in vitro and in vivo (24-27). The major AA-DNA adducts have been identified as 7-( (24, 26, 27) . The predominant DNA adduct produced in vivo, dA-AAI, is also the most persistent adduct in target tissues (forestomach, bladder and kidney), as well as in non-target tissues (liver and lung) (28) . Also, dA-AAI adducts were found in the kidney, ureter, bladder and other tissues of AAN patients at times long after AA exposure (5, 24, 25, 29) . This adduct has been shown to produce predominately A:T/T:A transversions (30, 31) . Sequence analysis and DNA-binding studies confirmed that AAs bind primarily to adenine residues in neutral reporter genes (LacZ and cII) and genes involved in the carcinogenic process (TP53 and H-Ras), producing A:T/T:A transversion mutations in vivo (8, 27, (32) (33) (34) (35) (36) (37) (38) .
Activation of proto-oncogenes and inactivation of tumour suppressor genes are considered to be critical molecular events in chemical carcinogenesis. Mutations in oncogenes and tumour suppressor genes have been implicated in the mechanism of AA-induced tumour development (7, 8, 32, 33, 37) . AAinitiated carcinogenesis in rodents is associated with activation of H-Ras by a specific A:T/T:A transversion mutation at the second position of codon 61 (CAA). H-Ras codon 61 CAA/CTA mutations have been found in all forestomach and ear duct tumours of rats treated with AAI, as well as in forestomach and lung tumours of treated mice (32, 33) . Moreover, A:T/T:A transversions have been identified in TP53 codon 139 of urothelial tumours of AAN and BEN patients, whose DNA also contains AA-DNA adducts (8, 37) . In vitro studies identified AA-induced A:T/T:A transversion mutations in the human TP53 gene of an embryonic cell line derived from the Hupki (human TP53 knock-in) mouse strain (39, 40) . Thus, the mutational profile observed in rodent neutral reporter gene assays and in human tumours is consistent with the AA-DNA adducts profile observed in vitro and in vivo in rodents and humans (41) .
Animal studies have been conducted to elucidate the sitespecificity of AA-induced carcinogenesis. AA is activated in kidney, liver, forestomach and other tissues; however, it mainly induces tumours in kidney and forestomach (11) . Studies reporting kidney and forestomach tumour incidence after AA exposure did not observe an increase in liver tumours, unless the rats also received a partial hepatectomy (42) . Rats treated orally with 0.1, 1.0 or 10 mg AA/kg bw/day for 3 months exhibited high incidences of tumours in the forestomach, kidney and urinary tract (72, 28 and 17%, respectively) (11) . When the same treatment regimen was used to treat male Big Blue transgenic rats (5 days/week for 12 weeks), up to 4-fold higher levels of total AA-DNA adducts were found in kidney than in liver. Also, an $2-fold higher cII gene mutation induction was observed in kidney as compared to liver. Sequence analysis of the cII gene mutants revealed that A:T/T:A transversion was the predominant type of mutation in the AA-treated rats, whereas GC/AT transition was the predominant mutation in the control rats (27, 34) .
Allele-specific competitive blocker-polymerase chain reaction (ACB-PCR) is a sensitive approach for directly quantifying specific rare base substitution mutations within a population of DNA molecules (43) . ACB-PCR has been used to characterise the induction of oncogene point mutations in response to carcinogen treatment. For example, ACB-PCR was used to quantify K-Ras codon 12 GGT/GAT and GGT/TGT mutations in A/J mouse lung following acute exposure to different doses of benzo[a]pyrene (B[a]P) (44) . Also, ACB-PCR was used to describe the dose-response relationship between simulated solar light exposure and induction of a ultraviolet (UV)-specific TP53 codon 270 CGT/TGT mutation in mouse skin tissues and to relate those measurements to the induction of simulated solar light-induced mouse skin tumours (45) . Thus, the ACB-PCR approach is a quantitative and sensitive tool to detect specific tumourassociated mutations as early reporters of tumour response (43) .
The current study employed the ACB-PCR approach to analyse H-Ras codon 61 CAA/CTA and K-Ras codon 12 GGT/GAT mutations in liver and kidney DNA of male Big Blue rats treated with 0, 0.1, 1.0 or 10.0 mg AA/kg bw. The specific goals of this study were (i) to characterise the AA dose-response using H-Ras and K-Ras mutation as endpoints in rat liver and kidney, as a means to elucidate the mechanism(s) of AA-induced carcinogenesis and (ii) to investigate whether spontaneous K-Ras mutation can be used as a generic reporter of AA-induced carcinogenesis.
Materials and methods

Animals
The liver and kidney tissues used in this study were those collected as part of studies conducted by Chen and Mei (27, 34) . Briefly, 6-week-old male Big Blue transgenic rats were purchased from Taconic Laboratories (Germantown, NY, USA). All animal procedures followed the recommendations of the National Center for Toxicological Research (NCTR) Institutional Animal Care and Use Committee for handling, maintenance, treatment and sacrifice. AA (CAS 313-67-7) was purchased from Sigma-Aldrich (St Louis, MO, USA) and the content of the test agent was 96% (40% AAI and 56% AAII). The structures of AAI and AAII can be found in (2) . Six rats per group were treated with AA (as its sodium salt) at concentrations of 0.1, 1.0 and 10.0 mg/kg bw by gavage, five times/week for 12 weeks and were sacrificed 1 day after the last treatment. Control rats were gavaged with 0.9% sodium chloride using the same schedule as for the AAtreated rats. The livers and kidneys were removed, immediately frozen in liquid nitrogen and stored at À80°C.
DNA isolation
Rat liver and kidney tissues were homogenised in an extraction buffer consisting of 1 mg/ml proteinase K (Sigma-Aldrich), 100 mM NaCl, 25 mM EDTA and 1% sodium dodecyl sulphate. The homogenate was incubated $16 h at 37°C, extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and ethanol precipitated. DNA samples were resuspended in 200 ll of a solution containing 10 mg/ml RNAse A (Sigma-Aldrich), 600 units/ml RNAse T1 (Sigma-Aldrich), 100 mM sodium acetate and 50 mM Tris-HCl, pH 8. For liver samples, this buffer also included 1 mg/ml a-amylase (Fluka Chemical, Ronkonkoma, NY, USA). Samples were incubated $16 h at 37°C and then extracted as described above. Each DNA sample was precipitated and then resuspended in 20 ll of 0.5Â TE buffer (5 mM Tris, 0.5 mM EDTA, pH 7.5). DNA samples were digested with EcoRI according to the manufacturer's instructions (New England Biolabs, Beverly, MA, USA). The digested DNAs were extracted as described above, ethanol precipitated, resuspended in 20 ll of 0.5Â TE buffer and concentrations were measured by UV absorbance at 260 nm.
Generating first-round PCR products EcoRI-digested liver and kidney genomic DNAs were used as the template for first-round PCR amplification of a 319 bp H-Ras gene segment encompassing exon 2 and part of intron 2, using primers RHu (5#-CCGGAAACAGGTAGT-CATTGA-3#) and RHd (5#-GAGGGGGATGGGGTGTA-3#). Each PCR reaction contained 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 20 mM Tris-HCl (pH 8.75), 2 mM MgSO 4 , 0.1% Triton X-100, 0.1 mg/ml bovine serum albumin, 0.2 mM dNTPs, 0.2 lM RD1 (5#-TTAAGCGTCGATGGAGGAGTT-3#), 0.2 lM RD2 (5#-GTCCTGCACCAGTAATATGC-3#) and 4 units of Cloned PfuUltraä Hotstart DNA Polymerase (Stratagene, La Jolla, CA, USA). The cycling conditions included heating for 2 min at 94°C, followed by 35 cycles of 1 min at 94°C, 1 min at 52°C and 1 min at 72°C.
EcoRI-digested liver and kidney genomic DNAs were used for first-round PCR amplification of a 304 bp K-Ras gene segment encompassing 50 bp of 5# flanking sequence, exon 1 and part of intron 1. The PCR conditions were identical to those described above, except the primers used were RKR2 (5#-CTGTACCGATGGTTCCCT-3#) and RKR5 (5#-ATATTTTATTATTTT-TATTATAAGGCCTG-3#). The PCR products were agarose gel purified using a GenecleanÒ Spin Kit (Q-Biogene, Vista, CA, USA). Single-use aliquots of first-round PCR products were prepared and repeatedly quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), until three measurements that varied ,10% from the group mean were obtained. All primers were purchased from Sigma-Genosys (The Woodlands, TX, USA).
Wild-type and mutant reference DNAs
Initially, in vitro mutagenesis was used to generate the mutant and wild-type (WT) reference DNAs. To generate an H-Ras WT reference DNA, in vitro mutagenesis was performed with RHu and an H-Ras WT mutagenesis primer (5#-CCGGAAACAGGTAGTCATTGATGGGGAGACGTGTTTACTGGACATCT TAGACACAGCAGGTCAAGAAGAGTATAGTGCCATGCGGGAC-3#), using control rat genomic DNA as template. Primer RHu and an H-Ras mutant mutagenesis primer (5#-CCGGAAACAGGTAGTCATTGATGGGGAGACGTG TTTACTGGACATCTTAGACACAGCAGGTCTAGAAGAGTATAGTGCCA TGCGGGAC-3#) were used to generate an H-Ras mutant reference DNA. Later, the H-Ras reference DNAs were used in an ACB-PCR to determine which control sample had the lowest codon 61 CTA MF. Genomic DNA from that sample was then used with primers RHu and RHd to synthesise a second WT reference DNA, which was used in the ACB-PCR analysis of all the unknown samples. The cycling conditions, purification and quantification were the same as described above.
K-Ras WT and mutant reference DNAs were generated by in vitro mutagenesis using control rat genomic DNA as template. Primer RD1 and a K-Ras WT mutagenesis primer (5#-ATATTTTATTATTTTTATTATAAGGCCTGCTGAA AATGACTGAGTATAAAC TTGTGGTAGTTGGAGCTGGTGGCGTAGG-3#) were used to generate the WT reference DNA. Primer RD1 and a K-Ras mutant mutagenesis primer (5#-ATATTTTATTATTTTTATTATAAGGCCTGCTGAA AATGACTGAGTATAAACTTGTGGTAGTTGGAGCTGATGGCGTAGG-3#) were used to generate the mutant reference DNA.
Allele-specific competitive blocker-polymerase chain reaction ACB-PCR quantification is based on the concurrent analysis of first-round PCR products generated from unknown samples and standards with defined ratios of mutant:WT DNA (i.e. MF standards). Purified mutant and WT DNA samples were mixed to generate standards with MFs of 10 À5 and 0. These standards and a no-DNA control were analysed in parallel with equal numbers of copies of unknown first-round PCR products. For H-Ras codon 61 CAA/CTA ACB-PCR, 4 Â 10 8 copies were analysed in each 50 ll reaction containing: 40 lM dNTPs, 1Â Stoffel buffer, 1.5 mM MgCl 2 , 0.1 mg/ml gelatin, 1.0 mg/ml Triton X-100, 500 nM primer UP-H (5#-GGAAACAGGTAGT-CATTGA-3#), 500 nM MSP-H (5#-fluorescein CATGGCACTA-TACTCTTCCA-3#) and 500 nM BP-H (5#-CATGGCACTATACTCTTCCdT-3#). Thermocycler conditions were 90 sec at 95°C, followed by 38 cycles of 30 sec at 94°C, 45 sec at 50°C and 1 min at 72°C. The H-Ras codon 61 CTA ACB-PCR product is 78 bp in length.
For K-Ras codon 12 GGT/GAT ACB-PCR, 2 Â 10 8 copies were analysed in each 50 ll reaction containing 80 lM dNTPs, 1Â Stoffel buffer, 1.5 mM MgCl 2 , 0.1 mg/ml gelatin, 1.0 mg/ml Triton X-100, 400 nM primer P4 (5#-GATTTACCTCT ATTGTTGGA-3#), 400 nM MSP-A (5#-fluorescein-CTTGTGGTAGTTGGAGCTTA-3#) and 366 nM BP-A (5#-CTTGTGGTAGTTGGAGCTTdG-3#). Thermocycler conditions were 90 sec at 95°C, followed by 36 cycles of 30 sec at 94°C, 45 sec at 42°C and 1 min at 72°C. The K-Ras codon 12 GAT ACB-PCR product is 105 bp in length.
Gel electrophoresis, image analysis and data collection Equal volumes of ACB-PCR products were analysed on non-denaturing 8% polyacrylamide gels. The fluorescent bands were visualised using a PharosFX Molecular Imager with an external blue laser (Bio-Rad Life Science, Hercules, CA, USA). Pixel intensities of the bands were quantified using Quantity OneÒ software and a locally averaged background correction (Bio-Rad, Hercules, CA, USA). After fluorescein-based quantification, gels were stained with Vistra Green (GE Healthcare Life Sciences, Piscataway, NJ, USA) to image the coelectrophoresed 25-bp DNA length marker (Invitrogen) and confirm the size of the ACB-PCR product.
Data analysis
The pixel intensities determined for the MF standards were plotted against their MFs on log-log plots. A trend line (exponential function) was fit to the data and the formula of the exponential function was used to calculate the MF in each unknown sample based on its pixel intensity. The arithmetic average of three independent MF measurements was calculated. The average MF in each DNA sample was log-transformed and the average log-transformed MF for the six rats in each treatment group was calculated. This value, converted back to scientific notation, is the geometric mean MF for each treatment group. Statistical differences in the average log-transformed MFs among treatment groups were analysed using Fisher's exact test, comparing number of samples with MFs . and ,10 À5 (Graphpad Prism 5, Graphpad Software, Inc.). Linear regression analysis was performed using Graphpad Prism 5 software.
Results
The ACB-PCR approach is based on parallel analysis of standards with defined MFs and unknowns, each containing the same total number of molecules Genomic DNAs from AA-treated (0.1, 1.0 and 10.0 mg/kg bw by gavage, five times/week for 12 weeks) and control Big Blue rat livers and kidneys were isolated. Pure WT and mutant reference DNAs for H-Ras codon 61 CAA/CTA or K-Ras codon 12 GGT/GAT were generated by PCR and then were combined to construct MF standards ranging from 10 À1 to 10
À5
. Each MF standard was analysed in duplicate, along with no-DNA control (pure WT standard). Using the standards, the ACB-PCR reaction conditions were optimised and then used to measure the H-Ras codon 61 CTA and K-Ras codon 12 GAT MF in 48 Big Blue rat liver and kidney samples (six rats in each group and four groups of 0, 0.1, 1.0 and 10.0 mg/kg bw AA), including three replicate ACB-PCR measurements per sample.
ACB-PCR preferentially amplifies the mutant allele using a primer (mutant-specific primer, MSP) that has more mismatches to the WT allele than to the mutant allele. The primer design used in the mutant-specific amplification of the HRas codon 61 CAA/CTA mutation is shown in Figure 1A and that for the K-Ras codon 12 GGT/GAT mutation is shown in Figure 1B . Because the MSP used in ACB-PCR is labelled with a 5#-fluorescein, ACB-PCR products are fluorescent and can be visualised following polyacrylamide gel electrophoresis.
AA-induced H-Ras codon 61 CAA/CTA mutation Six gels were used to quantify all the study samples for H-Ras codon 61 CAA/CTA MFs, with 12 MF standards per gel (i.e. replicate 10 À1 , 10 À2 , 10 À3 , 10 À4 , 10 À5 and 0 standard). The average r 2 value for the set of H-Ras codon 61 CTA standard curves was 0.9764 (range from 0.9704 to 0.9885). Results of four of the six replicate H-Ras codon 61 CTA ACB-PCR measurements are shown in Figure 2 . Results from liver and kidney of control rats and of rats exposed to 0.1 mg/kg bw AA, along with MF standards, are presented in Figure 2A . Results from liver and kidney of rats exposed to 1.0 and 10.0 mg/kg bw AA, along with MF standards, are presented in Figure 2B . A representative standard curve is presented in Figure 2C .
The H-Ras codon 61 CAA/CTA MF measurements in control and treated livers and kidneys are summarised in Table 1 and Figure 3 . Although some of the H-Ras codon 61 CTA ACB-PCR MFs measurements were below the lowest MF standard (10 À5 ), the calculated ACB-PCR MFs were used to estimate the geometric mean MF, the median MF and mutation prevalence for each treatment group ( À5 in zero of six rats in the 0.01 mg/kg bw AA dose group, in two of six rats in the 1.0 mg/kg bw AA dose group and in six of six rats in the 10.0 mg/kg bw AA dose group (Table 1, mutation prevalence) . The H-Ras codon 61 CTA geometric mean MFs were 1.30 Â 10 À6 , 1.14 Â 10 À5 and 5.81 Â 10 À4 for the 0.01, 1.0 and 10.0 mg/kg bw AA treatment groups, respectively (Table 1) . A significant trend of increasing H-Ras MF with increasing dose was observed (slope of linear regression line in log-log plot was significantly non-zero, P 5 0.0001, Figure 4A ). Because some of the H-Ras codon 61 CTA MF measurements were below the lowest MF standard, the distribution of samples . and ,10 À5 was tested using Fisher's exact test. Statistically significant differences were found between the 10 mg/kg bw dose group and each of the other treatment groups (for control and 0.1 mg/kg bw, P 5 0.0180; for 1.0 mg/kg bw, P 5 0.0303, using one-tailed tests).
In kidney, the H-Ras codon 61 CTA MF was .10 À5 in zero of six rats in the 0.01 mg/kg bw AA dose group, in two of six rats in the 1.0 mg/kg bw AA dose group and in five of six rats in the 10.0 mg/kg bw AA dose group (see Table 1 ). The H-Ras codon 61 CTA geometric mean MFs for the AA treatment groups were 5.05 Â 10 À6 , 1.72 Â 10 À5 and 1.32 Â 10 À4 for the 0.01, 1.0 and 10.0 mg/kg bw AA treatment groups, respectively (Table 1) . A significant trend of increasing H-Ras MF with increasing dose was observed (slope of linear regression line in log-log plot was significantly non-zero, P 5 0.0325, Figure 4B ). Treatment groups were analysed for the distribution of samples . and ,10 À5 relative to control samples. Statistically significant induction of H-Ras mutation was observed in kidneys of rats exposed to 10.0 mg/kg bw AA and each of the other treatment groups (for control and 0.1 mg/kg bw, P 5 0.0180; for 1.0 mg/ kg bw, P 5 0.0303, using one-tailed tests). K-Ras codon 12 GGT/GAT mutation Six gels were used to quantify K-Ras codon 12 GGT/GAT MF. The average r 2 value for the set of K-Ras codon 12 GAT standard curves was 0.9651 (range from 0.9600 to 0.9755). Results of four of the six replicate K-Ras codon 12 GAT ACB-PCR measurements are shown in Figure 5 . Samples from liver and kidney of control rats and rats exposed to 0.1 mg/kg bw AA, along with MF standards, are presented in Figure 5A . Samples from liver and kidney of rats exposed to 1.0 and 10.0 mg/kg bw AA, along with MF standards, are presented in Figure 5B . A representative standard curve is presented in Figure 5C .
The K-Ras codon 12 GGT/GAT MF measurements in control and AA-treated livers and kidneys are summarised in Table 1 and Figure 6 . None of the control kidney samples had a K-Ras codon 12 GAT MF .10
, whereas one control liver did have a K-Ras codon 12 GAT MF .10
. In liver, K-Ras codon 12 GAT MFs were .10 À5 in three of six rats in the 0.01 mg/kg bw AA dose group, in zero of six rats in the 1.0 mg/kg bw AA dose group and one of six rats in the 10.0 mg/kg bw AA dose group (Table 1 (Table 1) . No significant trend of increasing GAT MF with increasing dose was observed. The distribution of samples . and ,10 À5 for each treatment group was compared to controls using Fisher's exact test. No statistically significant differences between the control group and any AA treatment group were observed.
In kidney, K-Ras codon 12 GAT MFs were .10 À5 in four of six rats in the 0.01 mg/kg bw AA dose group, in zero of six rats in the 1.0 mg/kg bw AA dose group and in one of six rats in the 10.0 mg/kg bw AA dose group. The K-Ras codon 12 GAT geometric mean MFs were 2.62 Â 10 À5 , 3.04 Â 10 À6 and 6.02 Â 10 À6 for the 0.01, 1.0 and 10.0 mg/kg bw AA treatment groups, respectively ( Table 1) . Analysis of samples . and ,10 À5 using Fisher's exact test indicated that a significant induction of K-Ras mutation was observed in kidneys of rats exposed to 0.1 mg/kg bw AA, as compared to control rats (P 5 0.0303, in a one-sided test).
Correlation between DNA adducts, cII gene mutant frequencies and Ras MF Levels of DNA adducts and cII gene mutation were measured previously for each Big Blue rat used in the current study. This enabled direct comparisons of the levels of DNA adducts and cII gene mutation with the levels of H-Ras or K-Ras mutation induced in each rat. The total burden of DNA adducts induced in a particular rat by a given dose of AA was plotted against the HRas codon 61 CTA MF or K-Ras codon 12 GAT MF induced in the liver and kidney tissues of the same rat. Significant correlations between the total burden of DNA adducts and HRas MF measurements were observed for both liver (linear regression, P 5 0.0001) and kidney (linear regression, P 5 0.0325). No significant correlations between K-Ras codon 12 GAT MF and DNA adduct burden were observed ( Figure 7) . cII gene mutant frequency induced in a particular rat was plotted relative to the H-Ras codon 61 CTA MF or K-Ras codon 12 GAT MF induced in the liver and kidney of the same rat (Figure 8 ). Figure 8 shows significant correlations between the cII mutant frequency and H-Ras MF were observed in both liver and kidney (linear regression, P 5 0.0001). No significant correlations between K-Ras codon 12 GAT MF and cII mutant frequency were observed.
Discussion
In this study, ACB-PCR was employed to examine the ability of AA to induce two different oncogene mutations (H-Ras codon 61 CTA and K-Ras codon 12 GAT mutations) in order to determine whether the carcinogenic effect of AA can be measured at an early time point and to investigate whether spontaneous mutations can be used as generic reporters of carcinogenesis.
For H-Ras codon 61 CAA/CTA mutation, a low spontaneous background level was observed in the Big Blue rat liver and kidney and a significant dose-dependent induction of HRas MF was observed in AA-treated liver (linear regression, P , 0.001) and kidney (linear regression, P , 0.05). This finding is consistent with previous reports that H-Ras codon 61 CAA/CTA mutation is frequently induced by AA in rodent forestomach tumours and A:T/T:A transversion is the predominant mutational specificity induced by AA. Because this induction was measured only 12 weeks after exposure, this adds to the body of evidence that ACB-PCR can detect potentially carcinogenic effects at times considerably earlier Fig. 7 . Correlation between DNA adducts and Ras MF. AA-DNA adducts were determined by 32 P-postlabelling as reported (27) . The total burden of DNA adducts induced in each rat was plotted against the base 10 log of H-Ras codon 61 CTA MF induced in the liver (A) and kidney (B) of the same rat. The total burden of DNA adducts induced in each rat was plotted against the base 10 log of K-Ras codon 12 GAT MF induced in the liver (C) and kidney (D) of the same rat. than that needed for tumours to develop (43) . While it is not clear that every AA-induced H-Ras codon 61 CTA mutation will lead to the development of a tumour, the fact that this mutation is prevalent in AA-induced tumours argues that the early induction of the mutation is likely to be carcinogenic.
ACB-PCR measurements in control-and vehicle-treated animals published to date indicate Ras oncomutations are present in various tissues of control rodents at high spontaneous mutant fractions (MFs) relative to background measurements in neutral reporter gene (43, 44, (46) (47) (48) (49) . These findings are consistent with the idea that oncomutations confer a selective growth or survival advantage, allowing them to accumulate to higher levels than neutral reporter gene mutations. Therefore, pre-existing spontaneous oncomutations could potentially be sensitive generic reporters of carcinogenic effect.
For a number of mutagenic carcinogens, induction of spontaneous mutation (distinct from the primary mutational specificity of the chemical) has been noted. For example, in A/J mouse lung, the K-Ras codon 12 GAT MF increased in a B[a]P-dose-dependent manner, even though B[a]P primarily induces G/T mutation (44) . In Big Blue/F344 rat liver, the KRas codon 12 GAT MF significantly increased after Nhydroxy-2-acetylaminofluorene (N-OH-AAF) treatment, even though N-OH-AAF primarily induces G/T mutation (49) (50) (51) . Observations like these were the basis for investigating whether K-Ras codon 12 GAT mutation, a frequent spontaneous mutation, could be used as a generic reporter of carcinogenic effect. In the current study, K-Ras codon 12 GAT mutation did not increase in a dose-dependent manner. An increase was observed at low AA dose (0.1 mg/kg bw), which was statistically significant in kidney, even though induction of spontaneous mutations was not observed in the 1 or 10 mg/kg bw AA treatment groups.
The absence of an AA dose-dependent increase in K-Ras MF may be due to AA's cytotoxicity and/or ability to induce apoptosis. AA is known to form DNA adducts after metabolic activation and the resulting DNA adducts can block transcription and DNA replication (52, 53) . These effects may, in turn, induce cell cycle arrest or trigger apoptosis (52) . In vitro studies confirm that porcine and human kidney cell lines (LLC-PK1 cells and HKC cells, respectively) treated with 20 or 40 mg/l AAI have significantly higher percentages of apoptotic cells than controls (54, 55) . Increase in intracellular calcium ion concentration and caspase 3 and 7 activities are involved in the mechanism of AAIinduced TP53-dependent apoptosis (54, 56, 57) .
Research on the cytotoxicity of AA consistently indicates that 1 or 10 mg/kg bw AA are cytotoxic doses in rats (12) . Although one study found that 0.1 mg/kg bw/day for 16 months could induce chronic toxicity in rabbits, there is no evidence that 0.1 mg/kg bw/day for 3 months is cytotoxic in Big Blue rat liver or kidney (21) . Thus, at non-toxic doses, AA may induce the amplification of pre-existing K-Ras mutation as well as cause de novo induction of AA-specific mutation. At toxic doses, however, AA causes significant necrosis and/or apoptosis selecting against the pre-existing K-Ras mutation, whereas DNA adduct and de novo AA-specific mutation continue to accumulate despite the cytotoxicity. In this regard, it is important to note that H-Ras mutation induction was correlated with the DNA adduct levels induced at different AA doses, but no such correlation was observed for K-Ras.
The target organ specificity of AA carcinogenesis is of interest because AA induces DNA adducts and mutations in liver and kidney but induces tumours only in kidney (10, 11, 58) . Previously, Chen et al. determined AA-induced DNA adduct level and cII mutant frequency in liver and kidney for the same rats used in the current study (27, 34) . They reported AA dose-dependent increases in total DNA adducts and cII mutant frequency in both liver and kidney, although higher levels of both DNA adducts and cII mutants were detected in kidney. In the current study, H-Ras codon 61 CTA mutation was induced to similar levels in liver and kidney. This suggests factors in addition to DNA damage and mutation are necessary for tumour induction and that those factors account for the tissue specificity. Changes in gene expression, for example, may also drive tumour development. Microarray analysis was used to characterise differential responses to AA in kidney and liver (58) (59) (60) (61) (62) . Significant alterations of genes associated with defense response, apoptosis and immune response were found in kidney but not in liver, which may explain the tissue-specific carcinogenicity of AA.
The data obtained on AA-induced H-Ras mutation, viewed alongside other available data, provide definitive evidence that AA is a mutagenic and cytotoxic carcinogen. Bioactivated AA interacts with the exocyclic amino groups of deoxyadenosine and deoxyguanosine and leads to the preferential formation of adenine adducts (1, 16, 26) . A:T/T:A transversion mutations are the primary mutation specificity induced by AA and AAinduced tumours frequently carry H-Ras CAA/CTA mutations, which were detected by ACB-PCR shortly after exposure. Together, this dataset provides strong evidence that AA is a mutagenic carcinogen. Applying the same approaches to other carcinogens, therefore, may be a productive approach for understanding mode of action long before tumours may develop.
In conclusion, ACB-PCR measurement of H-Ras codon 61 CTA mutation provides an early measure of AA-induced carcinogenic effect. The K-Ras codon 12 GAT MF results indicate that frequent spontaneous mutations are not useful generic reporters of carcinogenic effects at cytotoxic doses. Nevertheless, the approach did detect a significant induction of K-Ras GAT at low dose (0.1 mg/kg bw), 12 weeks after exposure in the target tissue, providing additional support for the hypothesis that spontaneous mutation can be a generic reporter of carcinogenic effect when not measured under cytotoxic conditions. Finally, the present study illustrates how the ACB-PCR assay, when combined with other endpoints, has the potential to elucidate a chemical's cancer mode of action. 
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